Ainos, Inc. (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.
The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format. AI‐401 is engineered to target airway inflammation in conditions such as cystic fibrosis and other chronic respiratory diseases. In preclinical studies, the formulation demonstrated favorable pulmonary deposition and sustained release, and it has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of cystic fibrosis.
In addition to AI‐401, Ainos is exploring the application of its dry powder inhalation technology for other anti‐inflammatory and anti‐infective agents, with the goal of expanding its pipeline into multiple respiratory indications. The company collaborates with contract development and manufacturing organizations (CDMOs) to advance product candidates through formulation optimization, toxicology assessments and early clinical trials.
Founded in the United States, Ainos is headquartered in Philadelphia and serves patients and healthcare providers primarily in North America and Europe. The company’s management team comprises executives with extensive experience in respiratory drug development, regulatory affairs and commercial strategy. Ainos aims to leverage its inhalation platform to bring novel pulmonary therapies to market and address unmet medical needs in chronic lung disease.
AI Generated. May Contain Errors.
Free AIMD Stock Alerts